Perceptronix Announces Completion Of ClearVu Elite Clinical Study

VANCOUVER -- Perceptronix Medical Inc. (Perceptronix) announced today the completion of their clinical study entitled "Spectral Imaging of Early Lung Cancer and Pre-cancerous Lesions" using the Company's ClearVu Elite(TM) system. Perceptronix is a laboratory service and medical device company focused on the development and commercialization of effective technologies that can improve the early detection, localization, diagnosis and follow-up of cancer. The Company's initial focus is lung cancer. The study, which was conducted using the Perceptronix ClearVu Elite(TM) system, aimed to develop a robust decision-making algorithm based on estimating physiological and morphological properties of lung tissue from the non- conta...